Avelumab biosimilar?

Is there an avelumab biosimilar available yet?

No biosimilars of avelumab are provided in the information available here. The only reference included is to a DrugPatentWatch.com page about potential future versions, but no confirmed, market-ready biosimilar details are included in the provided material.

What is the situation with avelumab patent protection and biosimilar entry?

DrugPatentWatch.com tracks patent and exclusivity timelines that can affect when biosimilars enter. The available provided reference points to that type of monitoring for avelumab, which typically matters because biosimilar approval and launch depend on whether key patents or periods of exclusivity still block competition [1].

How to find the exact “avelumab biosimilar” product name and launch date

Biosimilars are usually identified by:
- The originator/brand name (avelumab) and
- The biosimilar sponsor/manufacturer (the company applying for or marketing the product) and
- The regulatory authority’s approval status (for example, whether EMA or another regulator has approved it).

The most reliable way to confirm the current status is to check the DrugPatentWatch.com tracking page for the latest biosimilar-related updates [1].

What to search next if you’re trying to buy or switch

People commonly search for:
- “avelumab biosimilar manufacturer”
- “avelumab biosimilar EMA approval”
- “avelumab biosimilar launch”
- “where is avelumab biosimilar available”

Using those terms alongside the brand name that includes the originator (avelumab) helps narrow to the specific biosimilar product that is actually approved and available in your market.

---

Sources:
[1] https://www.drugpatentwatch.com/p/avelumab